Scarica l'app Stockscreener
9.13
8.56%
0.72
Dopo l'orario di chiusura:
8.87
-0.26
-2.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.41
Aprire:
$8.47
Volume 24 ore:
412.53K
Relative Volume:
0.91
Capitalizzazione di mercato:
$259.50M
Reddito:
$67.22M
Utile/perdita netta:
$-65.78M
Rapporto P/E:
-3.8254
EPS:
-2.3867
Flusso di cassa netto:
$-79.02M
1 W Prestazione:
+8.69%
1M Prestazione:
+11.07%
6M Prestazione:
+10.13%
1 anno Prestazione:
-18.77%
Intervallo 1D:
$8.47
$9.17
Intervallo di 1 settimana:
$8.22
$9.17
Portata 52W:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
9.13 | 239.04M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | B. Riley Securities | Buy |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-10-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Downgrade | Citigroup | Buy → Neutral |
| 2025-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-28 | Iniziato | BTIG Research | Buy |
| 2024-08-12 | Iniziato | Leerink Partners | Outperform |
| 2023-12-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-07-24 | Iniziato | William Blair | Outperform |
| 2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Ripresa | Wells Fargo | Overweight |
| 2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
| 2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Iniziato | Wells Fargo | Overweight |
| 2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
| 2020-12-08 | Reiterato | B. Riley Securities | Buy |
| 2020-12-07 | Reiterato | B. Riley Securities | Buy |
| 2020-10-26 | Iniziato | Barclays | Overweight |
| 2020-10-06 | Iniziato | Citigroup | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-30 | Ripresa | ROTH Capital | Buy |
| 2020-07-16 | Iniziato | Raymond James | Outperform |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
| 2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-07 | Iniziato | Guggenheim | Buy |
| 2020-02-06 | Iniziato | Guggenheim | Buy |
| 2019-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Repor - GuruFocus
MSN Money - MSN
ARCT Stock Price, Quote & Chart | ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) - ChartMill
Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Arcturus Therapeutics Holdings (ARCT) price target decreased by 27.17% to 25.78 - MSN
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May - PharmiWeb.com
Arcturus plans after-hours results and a 4:30 p.m. ET call May 7 - Stock Titan
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026 - Business Wire
How Arcturus Therapeutics Holdings Inc. (ARCT) Affects Rotational Strategy Timing - Stock Traders Daily
ARCT Price Today: Arcturus Therapeutics Holdings Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Arcturus (NASDAQ: ARCT) schedules 2026 virtual meeting on pay, board and auditor - Stock Titan
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Navigating a 170% Potential Upside with Innovative Biotechnology - DirectorsTalk Interviews
(ARCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Published on: 2026-04-10 06:58:22 - baoquankhu1.vn
Is Arc Tx (ARCT) Stock Good for Portfolio | Price at $8.40, Down 1.22%Breakout Confirmation - Cổng thông tin điện tử tỉnh Lào Cai
Should I Buy Arc Tx (ARCT) Stock Now | Price at $8.44, Up 5.14%Trending Buy Opportunities - Xã Châu Thành
HC Wainwright & Co. Downgrades Arcturus Therapeutics Holdings (ARCT) - MSN
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript - MSN
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT - marketbeat.com
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Exploring a 196.82% Potential Upside with Cutting-Edge RNA Therapies - DirectorsTalk Interviews
ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics features Chief Medical Officer in The Bonnell Foundation podcast discussion - Traders Union
BTIG Maintains Arcturus Therapeutics Holdings (ARCT) Buy Recommendation - MSN
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics By Investing.com - Investing.com South Africa
Cathie Wood’s ARK sells Nvidia stock, buys Arcturus Therapeutics - Investing.com
ARCT.O - Reuters
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vanguard disaggregates holdings; reports 0 shares — Arcturus (ARCT) - Stock Titan
New Highs: Is Arcturus Therapeutics Holdings Inc forming a breakout pattern2026 Historical Comparison & Accurate Buy Signal Notifications - baoquankhu1.vn
Aug Setups: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Understanding the Setup: (ARCT) and Scalable Risk - Stock Traders Daily
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - MarketBeat
Arcturus Therapeutics at the 38th Annual Roth Conference: Strategic Shift to Rare Diseases - Investing.com Canada
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool
Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data - MSN
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial - marketbeat.com
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Cathie Wood’s ARK adds 10x Genomics stock, trims Arcturus By Investing.com - Investing.com South Africa
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation - MSN
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):